Eloralintide
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Eli Lilly · Phase 1 · Not yet recruiting · Enrollment 60
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Macupatide + placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Eloralintide + placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Macupatide Dose A + Eloralintide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Macupatide Dose B + Eloralintide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |